Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while ...
Biopharma manufacturing today is being asked to move faster, accommodate increasingly complex modalities, and respond more ...
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s ...
Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the U.S. to reduce proteinuria in adults ...
Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim ...
METiS TechBio announced a strategic collaboration with Eli Lilly and Company focused on researching and discovering novel lipid nanoparticle (LNP)-based delivery solutions designed to enable ...
Fox Rothschild's Mark Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and ...
Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure. President Trump’s Most-Favored Nation (MFN) initiative continues to ...
AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence ...
Merck KGaA, Darmstadt, Germany, agrees to acquire Silence Therapeutics for roughly $1.3 billion, gaining a siRNA asset, ...
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona ...
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results